Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Non-Current Assets (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Other Non-Current Assets for 12 consecutive years, with $836000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 88.8% to $836000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $836000.0, a 88.8% decrease, with the full-year FY2024 number at $12.3 million, changed N/A from a year prior.
  • Other Non-Current Assets was $836000.0 for Q3 2025 at Theravance Biopharma, roughly flat from $836000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $13.8 million in Q1 2025 to a low of $833000.0 in Q2 2021.
  • A 5-year average of $4.9 million and a median of $2.3 million in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: surged 1346.53% in 2023, then tumbled 88.8% in 2025.
  • Theravance Biopharma's Other Non-Current Assets stood at $833000.0 in 2021, then surged by 728.21% to $6.9 million in 2022, then surged by 44.95% to $10.0 million in 2023, then increased by 22.86% to $12.3 million in 2024, then crashed by 93.2% to $836000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Other Non-Current Assets are $836000.0 (Q3 2025), $836000.0 (Q2 2025), and $13.8 million (Q1 2025).